Cargando…

Comparing Findings From a Friends of Cancer Research Exploratory Analysis of Real-World End Points With the Cancer Analysis System in England

This study compared real-world end points extracted from the Cancer Analysis System (CAS), a national cancer registry with linkage to national mortality and other health care databases in England, with those from diverse US oncology data sources, including electronic health care records, insurance c...

Descripción completa

Detalles Bibliográficos
Autores principales: Horvat, Pia, Gray, Christen M., Lambova, Alexandrina, Christian, Jennifer B., Lasiter, Laura, Stewart, Mark, Allen, Jeff, Clarke, Paul, Chen, Cong, Reich, Adam
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer Health 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8763340/
https://www.ncbi.nlm.nih.gov/pubmed/34860576
http://dx.doi.org/10.1200/CCI.21.00013
_version_ 1784633914660225024
author Horvat, Pia
Gray, Christen M.
Lambova, Alexandrina
Christian, Jennifer B.
Lasiter, Laura
Stewart, Mark
Allen, Jeff
Clarke, Paul
Chen, Cong
Reich, Adam
author_facet Horvat, Pia
Gray, Christen M.
Lambova, Alexandrina
Christian, Jennifer B.
Lasiter, Laura
Stewart, Mark
Allen, Jeff
Clarke, Paul
Chen, Cong
Reich, Adam
author_sort Horvat, Pia
collection PubMed
description This study compared real-world end points extracted from the Cancer Analysis System (CAS), a national cancer registry with linkage to national mortality and other health care databases in England, with those from diverse US oncology data sources, including electronic health care records, insurance claims, unstructured medical charts, or a combination, that participated in the Friends of Cancer Research Real-World Evidence Pilot Project 1.0. Consistency between data sets and between real-world overall survival (rwOS) was assessed in patients with immunotherapy-treated advanced non–small-cell lung cancer (aNSCLC). PATIENTS AND METHODS: Patients with aNSCLC, diagnosed between January 2013 and December 2017, who initiated treatment with approved programmed death ligand-1 (PD-[L]1) inhibitors until March 2018 were included. Real-world end points, including rwOS and real-world time to treatment discontinuation (rwTTD), were assessed using Kaplan-Meier analysis. A synthetic data set, Simulacrum, on the basis of conditional random sampling of the CAS data was used to develop and refine analysis scripts while protecting patient privacy. RESULTS: Characteristics (age, sex, and histology) of the 2,035 patients with immunotherapy-treated aNSCLC included in the CAS study were broadly comparable with US data sets. In CAS, a higher proportion (46.7%) of patients received a PD-(L)1 inhibitor in the first line than in US data sets (18%-30%). Median rwOS (11.4 months; 95% CI, 10.4 to 12.7) and rwTTD (4.9 months; 95% CI, 4.7 to 5.1) were within the range of US-based data sets (rwOS, 8.6-13.5 months; rwTTD, 3.2-7.0 months). CONCLUSION: The CAS findings were consistent with those from US-based oncology data sets. Such consistency is important for regulatory decision making. Differences observed between data sets may be explained by variation in health care settings, such as the timing of PD-(L)1 approval and reimbursement, and data capture.
format Online
Article
Text
id pubmed-8763340
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Wolters Kluwer Health
record_format MEDLINE/PubMed
spelling pubmed-87633402022-01-18 Comparing Findings From a Friends of Cancer Research Exploratory Analysis of Real-World End Points With the Cancer Analysis System in England Horvat, Pia Gray, Christen M. Lambova, Alexandrina Christian, Jennifer B. Lasiter, Laura Stewart, Mark Allen, Jeff Clarke, Paul Chen, Cong Reich, Adam JCO Clin Cancer Inform ORIGINAL REPORTS This study compared real-world end points extracted from the Cancer Analysis System (CAS), a national cancer registry with linkage to national mortality and other health care databases in England, with those from diverse US oncology data sources, including electronic health care records, insurance claims, unstructured medical charts, or a combination, that participated in the Friends of Cancer Research Real-World Evidence Pilot Project 1.0. Consistency between data sets and between real-world overall survival (rwOS) was assessed in patients with immunotherapy-treated advanced non–small-cell lung cancer (aNSCLC). PATIENTS AND METHODS: Patients with aNSCLC, diagnosed between January 2013 and December 2017, who initiated treatment with approved programmed death ligand-1 (PD-[L]1) inhibitors until March 2018 were included. Real-world end points, including rwOS and real-world time to treatment discontinuation (rwTTD), were assessed using Kaplan-Meier analysis. A synthetic data set, Simulacrum, on the basis of conditional random sampling of the CAS data was used to develop and refine analysis scripts while protecting patient privacy. RESULTS: Characteristics (age, sex, and histology) of the 2,035 patients with immunotherapy-treated aNSCLC included in the CAS study were broadly comparable with US data sets. In CAS, a higher proportion (46.7%) of patients received a PD-(L)1 inhibitor in the first line than in US data sets (18%-30%). Median rwOS (11.4 months; 95% CI, 10.4 to 12.7) and rwTTD (4.9 months; 95% CI, 4.7 to 5.1) were within the range of US-based data sets (rwOS, 8.6-13.5 months; rwTTD, 3.2-7.0 months). CONCLUSION: The CAS findings were consistent with those from US-based oncology data sets. Such consistency is important for regulatory decision making. Differences observed between data sets may be explained by variation in health care settings, such as the timing of PD-(L)1 approval and reimbursement, and data capture. Wolters Kluwer Health 2021-12-03 /pmc/articles/PMC8763340/ /pubmed/34860576 http://dx.doi.org/10.1200/CCI.21.00013 Text en © 2021 by American Society of Clinical Oncology https://creativecommons.org/licenses/by-nc-nd/4.0/Creative Commons Attribution Non-Commercial No Derivatives 4.0 License: https://creativecommons.org/licenses/by-nc-nd/4.0/
spellingShingle ORIGINAL REPORTS
Horvat, Pia
Gray, Christen M.
Lambova, Alexandrina
Christian, Jennifer B.
Lasiter, Laura
Stewart, Mark
Allen, Jeff
Clarke, Paul
Chen, Cong
Reich, Adam
Comparing Findings From a Friends of Cancer Research Exploratory Analysis of Real-World End Points With the Cancer Analysis System in England
title Comparing Findings From a Friends of Cancer Research Exploratory Analysis of Real-World End Points With the Cancer Analysis System in England
title_full Comparing Findings From a Friends of Cancer Research Exploratory Analysis of Real-World End Points With the Cancer Analysis System in England
title_fullStr Comparing Findings From a Friends of Cancer Research Exploratory Analysis of Real-World End Points With the Cancer Analysis System in England
title_full_unstemmed Comparing Findings From a Friends of Cancer Research Exploratory Analysis of Real-World End Points With the Cancer Analysis System in England
title_short Comparing Findings From a Friends of Cancer Research Exploratory Analysis of Real-World End Points With the Cancer Analysis System in England
title_sort comparing findings from a friends of cancer research exploratory analysis of real-world end points with the cancer analysis system in england
topic ORIGINAL REPORTS
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8763340/
https://www.ncbi.nlm.nih.gov/pubmed/34860576
http://dx.doi.org/10.1200/CCI.21.00013
work_keys_str_mv AT horvatpia comparingfindingsfromafriendsofcancerresearchexploratoryanalysisofrealworldendpointswiththecanceranalysissysteminengland
AT graychristenm comparingfindingsfromafriendsofcancerresearchexploratoryanalysisofrealworldendpointswiththecanceranalysissysteminengland
AT lambovaalexandrina comparingfindingsfromafriendsofcancerresearchexploratoryanalysisofrealworldendpointswiththecanceranalysissysteminengland
AT christianjenniferb comparingfindingsfromafriendsofcancerresearchexploratoryanalysisofrealworldendpointswiththecanceranalysissysteminengland
AT lasiterlaura comparingfindingsfromafriendsofcancerresearchexploratoryanalysisofrealworldendpointswiththecanceranalysissysteminengland
AT stewartmark comparingfindingsfromafriendsofcancerresearchexploratoryanalysisofrealworldendpointswiththecanceranalysissysteminengland
AT allenjeff comparingfindingsfromafriendsofcancerresearchexploratoryanalysisofrealworldendpointswiththecanceranalysissysteminengland
AT clarkepaul comparingfindingsfromafriendsofcancerresearchexploratoryanalysisofrealworldendpointswiththecanceranalysissysteminengland
AT chencong comparingfindingsfromafriendsofcancerresearchexploratoryanalysisofrealworldendpointswiththecanceranalysissysteminengland
AT reichadam comparingfindingsfromafriendsofcancerresearchexploratoryanalysisofrealworldendpointswiththecanceranalysissysteminengland